logo

HELPING PATIENTS ENROLL IN THE EYE DROP SUPPORTIVE CARE PROGRAM

Discover the steps doctors can take to help patients access free eye drops for the duration of their therapy.

Discover the steps doctors can take to help patients access free eye drops for the duration of their therapy.

  • VIDEO TRANSCRIPT | 13:03

    SOUND FX: 2 heartbeats

    ANIMATION: GSK Oncology On Demand for US HCPs

     

    VO: INDICATION. BLENREP (belantamab mafodotin-blmf) is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

     

    This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

     

    IMPORTANT SAFETY INFORMATION.

    WARNING: OCULAR TOXICITY.

    BLENREP caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms such as blurred vision and dry eyes.

     

    Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold BLENREP until improvement and resume, or permanently discontinue, based on severity.

     

    Because of the risk of ocular toxicity, BLENREP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP REMS.

     

    Please see IMPORTANT SAFETY INFORMATION and full Prescribing Information, including BOXED WARNING.

    TEXT ON SCREEN: BLENREP

    belantamab

    mafodotin-blmf

    for injection 100 mg

     

    INDICATION

    BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

     

    This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

     

    IMPORTANT SAFETY INFORMATION

    WARNING: OCULAR TOXICITY

    BLENREP caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms such as blurred vision and dry eyes.

     

    Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold BLENREP until improvement and resume, or permanently discontinue, based on severity.

     

    Because of the risk of ocular toxicity, BLENREP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP REMS.

     

    Please see IMPORTANT SAFETY INFORMATION and full Prescribing Information, including BOXED WARNING.

    VO: Have you told your patients about BLENREP’s Eye Drop Supportive Care Program?

    TEXT ON SCREEN:  EYE DROP SUPPORTIVE CARE PROGRAM

    Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.

     

    VO: It’s a program that provides free eye drops to patients throughout therapy.

    TEXT ON SCREEN: EYE DROPS

    60 vials of eye drops every 60 days

     

    VO: Patients will need an ophthalmic exam at baseline, prior to each dose, and promptly for worsening symptoms.

    TEXT ON SCREEN: EYE DROPS

    Patients will need an ophthalmic exam at baseline, prior to each dose, and promptly for worsening symptoms.

     

    VO: During treatment with BLENREP

    TEXT ON SCREEN:  Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.

     

    VO: it’s important for patients to apply preservative-free lubricant eye drops at least four times a day

    TEXT ON SCREEN: FOUR TIMES PER DAY

    Starting with the 1st infusion and continuing until the end of treatment

     

    VO: starting with the 1st infusion and continuing until the end of treatment.

    TEXT ON SCREEN: Starting with the 1st infusion and continuing until the end of treatment

     

    VO: The Eye Drop Supportive Care Program can help them do just that.

    TEXT ON SCREEN: EYE DROP SUPPORTIVE CARE PROGRAM

     

    VO: Help patients enroll in 3 easy steps:

    TEXT ON SCREEN: HELP PATIENTS ENROLL IN 3 EASY STEPS

     

    VO: Print the Eye Drop Supportive Care Program enrollment form

    TEXT ON SCREEN: STEP 1

    PRINT

    View Enrollment Form

     

    VO: from BLENREPHCP.com.

    TEXT ON SCREEN: Image of the front of the BLENREP Eye Drop Supportive Care Program form is displayed. The following text matches the text on the front of this form.

    BLENREP Eye Drop Supportive Care Program

     

    BLENREP

    belantamab

    mafodotin-blmf

    for injection 100 mg

     

    This form must be completed, signed, and submitted before you can receive preservative-free lubricant eye drops. Print and submit the completed form by fax at 1-888-635-1044.

     

    Patient Information

    Fields marked * are REQUIRED

    First Name*:

    Middle Initial:

    Last Name*:

    Date of Birth (MM/DD/YYYY)*:

    Phone Number*:

    Email Address:
    Address*:

    City*:

    State*:

    ZIP Code:

    Shipping address is same as mailing address (above).

    Preferred shipping address entered below.

    Preferred Shipping Address:
    City:
    State:

    ZIP Code:

     

    Patient Authorization to Use Health Information

     

    By signing this form, I agree to allow my doctors, doctors’ offices, hospitals, infusion

    sites, specialty distributor(s), and authorized staff supporting these entities (collectively

    “Healthcare Providers”), to use and disclose my health information to GSK and its agents,

    authorized representatives, and contractors (collectively “GSK”) so that GSK can use and

    disclose my health information for purposes of providing me with preservative-free lubricant

    eye drops. The following activities are included:

     

    1. Utilizing my REMS information such as REMS ID, REMS Enrollment Status, REMS Enrollment Form, Patient Status Forms, Eye Care Professional Consult Forms, and the REMS Checklist completed by my Healthcare Providers.
    2. Communicating with my Healthcare Providers about my BLENREP prescription and medical condition.
    3. Disclosing my information to third parties if required by law.

     

    Access to this form at www.blenrephcp.com

    Continued on reverse.

     

    Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.

     

    VO: Complete the form with your patient.

    TEXT ON SCREEN: STEP 2

    *Remember to give your patient a copy of the form for their records!

     

    Animation showing the front of the BLENREP Eye Drop Supportive Care Program form being completed is shown.

     

    TEXT ON SCREEN: STEP 2

    *Remember to give your patient a copy of the form for their records!

     

    Image of the back of the BLENREP Eye Drop Supportive Care Program form is displayed. The following text matches the text on the front of this form. Animation showing the back of the BLENREP Eye Drop Supportive Care Program form being completed is shown.

     

    Patient Authorization to Use Health Information (cont’d)

     

    By signing this authorization, I acknowledge my understanding that:

    • My Healthcare Providers will not and may not condition my treatment, payment for treatment, or eligibility for or enrollment in benefits on whether I sign this patient authorization.
    • Once information about me is released to GSK based on this authorization, federal privacy laws may no longer protect my information and may not prevent GSK from further disclosing my information. However, I understand that GSK has agreed to use or disclose information received only for the purposes described in this authorization or as required by law.
    • This authorization will remain in effect for two (2) years after I sign it (unless a shorter period is required by state law) or for as long as I participate in the eye drop program, whichever is longer.
    • I have the right to revoke this authorization at any time by mailing a signed, written statement of my revocation to United BioSource LLC, BLENREP Eye Drop Supportive Care Program, 200 Pinecrest Plaza Morgantown, WV 26505 US, but such a revocation would end my eligibility to participate in the eye drop program. (The revocation process may also be initiated by calling the Coordinating Center at 1-855-209-9188). Revoking this authorization will prohibit further disclosures by my Healthcare Providers based on this authorization after the date a written revocation is received but will not apply to the extent that they have already taken action in reliance on this authorization. After this authorization is revoked, I understand that information provided to GSK prior to the revocation may be disclosed within GSK to maintain records of my participation.

     

    The patient, or the patient’s legal guardian, MUST sign this form in order for the patient to receive preservative-free lubricant eye drops. If a legal guardian signs for the patient,please indicate relationship to the patient.

     

    Patient Signature and Acknowledgment

    By signing this form, I agree that GSK can utilize the health information described above,

    including my REMS information, to provide me free preservative-free lubricant eye drops.

    Patient / Legal Guardian Signature

    PRINT NAME

    Date

    MONTH/DAY/YEAR

    Trademarks are owned by or licensed to the GSK group of companies.

    ©2020 GSK or licensor.

    BLMLTR200018 October 2020

    Produced in USA. 0002-0009-50

     

    BLENREP

    belantamab

    mafodotin-blmf

    for injection 100 mg

     

    VO: Fax the form

    TEXT ON SCREEN: STEP 3

     

    VO: to 1-888-635-1044.

    TEXT ON SCREEN: FAX TO:

    1-888-635-1044

     

    VO: Once the patient is enrolled, the patient is expected to receive the shipment within 4 business days.

    TEXT ON SCREEN: MON 1

    TUE 2

    WED 3

    THU 4

    EYE DROPS

     

    VO: After that, your patient will continue to receive an eye drop shipment in the mail

    TEXT ON SCREEN: EYE DROPS

    These eye drops are intended to serve as a sample. If your patient runs out during treatment, then your patient will need to purchase additional preservative-free eye drops. There are instructions about purchasing the correct over-the-counter drops in the BLENREP REMS Patient Guide.

    VO: every 60 days throughout therapy.

    TEXT ON SCREEN: EVERY 60 DAYS

    These eye drops are intended to serve as a sample. If your patient runs out during treatment, then your patient will need to purchase additional preservative-free eye drops. There are instructions about purchasing the correct over-the-counter drops in the BLENREP REMS Patient Guide.

     

    VO: Tell your patients about an additional supportive resource during treatment with BLENREP.

    TEXT ON SCREEN: Enroll your patients at

     

    VO: Download the enrollment form and get your patient started today at www.BLENREPHCP.com

    TEXT ON SCREEN: Enroll your patients at

    BLENREPHCP.com

     

    VO: WARNINGS AND PRECAUTIONS.

    Ocular Toxicity: Ocular adverse reactions occurred in 77% of the 218 patients in the pooled safety population. Ocular adverse reactions included keratopathy (76%), changes in visual acuity (55%), blurred vision (27%), and dry eye (19%). Among patients with keratopathy (n = 165), 49% had ocular symptoms, 65% had clinically relevant visual acuity changes (decline of 2 or more lines on Snellen Visual Acuity in any eye), and 34% had both ocular symptoms and visual acuity changes.

     

    Keratopathy: Keratopathy was reported as Grade 1 in 7% of patients, Grade 2 in 22%, Grade 3 in 45%, and Grade 4 in 0.5% per the KVA scale. Cases of corneal ulcer (ulcerative and infective keratitis) have been reported. Most keratopathy events developed within the first 2 treatment cycles (cumulative incidence of 65% by Cycle 2). Of the patients with Grade 2 to 4 keratopathy (n = 149), 39% recovered to Grade 1 or lower after median follow-up of 6.2 months. Of the 61% who had ongoing keratopathy, 28% were still on treatment, 9% were in follow-up, and in 24% the follow-up ended due to death, study withdrawal, or lost to follow-up. For patients in whom events resolved, the median time to resolution was 2 months (range: 11 days to 8.3 months).

     

    Visual Acuity Changes: A clinically significant decrease in visual acuity of worse than 20/40 in the better-seeing eye was observed in 19% of the 218 patients and of 20/200 or worse in the better-seeing eye in 1.4%. Of the patients with decreased visual acuity of worse than 20/40, 88% resolved and the median time to resolution was 22 days (range: 7 days to 4.2 months). Of the patients with decreased visual acuity of 20/200 or worse, all resolved and the median duration was 22 days (range: 15 to 22 days).

     

    Monitoring and Patient Instruction: Conduct ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms. Perform baseline examinations within 3 weeks prior to the first dose. Perform each follow-up examination at least 1 week after the previous dose and within 2 weeks prior to the next dose. Withhold BLENREP until improvement and resume at same or reduced dose, or consider permanently discontinuing based on severity. Advise patients to use preservative-free lubricant eye drops at least 4 times a day starting with the first infusion and continuing until end of treatment. Avoid use of contact lenses unless directed by an ophthalmologist. Changes in visual acuity may be associated with difficulty for driving and reading. Advise patients to use caution when driving or operating machinery. BLENREP is only available through a restricted program under a REMS.

     

    Thrombocytopenia: Thrombocytopenia occurred in 69% of 218 patients in the pooled safety population, including Grade 2 in 13%, Grade 3 in 10%, and Grade 4 in 17%. The median time to onset of the first thrombocytopenic event was 26.5 days. Thrombocytopenia resulted in dose reduction, dose interruption, or discontinuation in 9%, 2.8%, and 0.5% of patients, respectively. Grade 3 to 4 bleeding events occurred in 6% of patients, including Grade 4 in 1 patient. Fatal adverse reactions included cerebral hemorrhage in 2 patients. Perform complete blood cell counts at baseline and during treatment as clinically indicated. Consider withholding and/or reducing the dose based on severity.

     

    Infusion-Related Reactions: Infusion-related reactions occurred in 18% of 218 patients in the pooled safety population, including Grade 3 in 1.8%. Monitor patients for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion and provide supportive treatment. Once symptoms resolve, resume at a lower infusion rate. Administer premedication for all subsequent infusions. Discontinue BLENREP for life-threatening infusion-related reactions and provide appropriate emergency care.

     

    Embryo-Fetal Toxicity: Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose. Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.

     

    ADVERSE REACTIONS

    The pooled safety population described in Warnings and Precautions reflects exposure to BLENREP at a dosage of 2.5 mg/kg or 3.4 mg/kg (1.4 times the recommended dose) administered intravenously once every 3 weeks in 218 patients in DREAMM-2. Of these patients, 194 received a liquid formulation (not the approved dosage form) rather than the lyophilized powder.

     

    Patients received BLENREP at the recommended dosage of 2.5 mg/kg administered intravenously once every 3 weeks (n = 95). Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received BLENREP; keratopathy (2.1%) was the most frequent adverse reaction resulting in permanent discontinuation. Dosage interruptions due to an adverse reaction occurred in 54% of patients who received BLENREP. Adverse reactions which required a dosage interruption in >3% of patients included keratopathy (47%), blurred vision (5%), dry eye (3.2%), and pneumonia (3.2%). Dose reductions due to an adverse reaction occurred in 29% of patients. Adverse reactions which required a dose reduction in >3% of patients included keratopathy (23%) and thrombocytopenia (5%).

     

    The most common adverse reactions (≥20%) were keratopathy (71%), decreased visual acuity (53%), nausea (24%), blurred vision (22%), pyrexia (22%), infusion-related reactions (21%), and fatigue (20%). The most common Grade 3 or 4 (≥5%) laboratory abnormalities were lymphocytes decreased (22%), platelets decreased (21%), hemoglobin decreased (18%), neutrophils decreased (9%), creatinine increased (5%), and gamma-glutamyl transferase increased (5%).

     

    Serious adverse reactions occurred in 40% of patients who received BLENREP. Serious adverse reactions in >3% of patients included pneumonia (7%), pyrexia (6%), renal impairment (4.2%), sepsis (4.2%), hypercalcemia (4.2%), and infusion-related reactions (3.2%). Fatal adverse reactions occurred in 3.2% of patients, including sepsis (1%), cardiac arrest (1%), and lung infection (1%).

     

    USE IN SPECIFIC POPULATIONS

     

    Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with BLENREP and for 3 months after the last dose.

     

    Females and Males of Reproductive Potential: Based on findings in animal studies, BLENREP may impair fertility in females and males.

     

    Geriatric Use: Of the 218 patients who received BLENREP in DREAMM-2, 43% were aged 65 to less than 75 years and 17% were aged 75 years and older. Keratopathy occurred in 80% of patients aged less than 65 years and 73% of patients aged 65 years and older. Among the 95 patients who received BLENREP at the 2.5-mg/kg dose, keratopathy occurred in 67% of patients aged less than 65 years and 73% of patients aged 65 years and older.

     

    Renal or Hepatic Impairment: The recommended dosage has not been established in patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2) or end-stage renal disease (ESRD) with eGFR <15 mL/min/1.73 m2 not on dialysis or requiring dialysis. The recommended dosage has not been established in patients with moderate or severe hepatic impairment (total bilirubin >1.5 × ULN and any AST).

     

    Please see full Prescribing Information, including BOXED WARNING.

    TEXT ON SCREEN (Scrolling ISI): IMPORTANT SAFETY INFORMATION (CONT’D)
    WARNINGS AND PRECAUTIONS

    Ocular Toxicity: Ocular adverse reactions occurred in 77% of the 218 patients in the pooled safety population. Ocular adverse reactions included keratopathy (76%), changes in visual acuity (55%), blurred vision (27%), and dry eye (19%). Among patients with keratopathy (n = 165), 49% had ocular symptoms, 65% had clinically relevant visual acuity changes (decline of 2 or more lines on Snellen Visual Acuity in any eye), and 34% had both ocular symptoms and visual acuity changes.

     

    Keratopathy: Keratopathy was reported as Grade 1 in 7% of patients, Grade 2 in 22%, Grade 3 in 45%, and Grade 4 in 0.5% per the KVA scale. Cases of corneal ulcer (ulcerative and infective keratitis) have been reported. Most keratopathy events developed within the first 2 treatment cycles (cumulative incidence of 65% by Cycle 2). Of the patients with Grade 2 to 4 keratopathy (n = 149), 39% recovered to Grade 1 or lower after median follow-up of 6.2 months. Of the 61% who had ongoing keratopathy, 28% were still on treatment, 9% were in follow-up, and in 24% the follow-up ended due to death, study withdrawal, or lost to follow-up. For patients in whom events resolved, the median time to resolution was 2 months (range: 11 days to 8.3 months).

     

    Visual Acuity Changes: A clinically significant decrease in visual acuity of worse than 20/40 in the better-seeing eye was observed in 19% of the 218 patients and of 20/200 or worse in the better-seeing eye in 1.4%. Of the patients with decreased visual acuity of worse than 20/40, 88% resolved and the median time to resolution was 22 days (range: 7 days to 4.2 months). Of the patients with decreased visual acuity of 20/200 or worse, all resolved and the median duration was 22 days (range: 15 to 22 days).

     

    Monitoring and Patient Instruction: Conduct ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms. Perform baseline examinations within 3 weeks prior to the first dose. Perform each follow-up examination at least 1 week after the previous dose and within 2 weeks prior to the next dose. Withhold BLENREP until improvement and resume at same or reduced dose, or consider permanently discontinuing based on severity. Advise patients to use preservative-free lubricant eye drops at least 4 times a day starting with the first infusion and continuing until end of treatment. Avoid use of contact lenses unless directed by an ophthalmologist. Changes in visual acuity may be associated with difficulty for driving and reading. Advise patients to use caution when driving or operating machinery. BLENREP is only available through a restricted program under a REMS.

    Thrombocytopenia:
    Thrombocytopenia occurred in 69% of 218 patients in the pooled safety population, including Grade 2 in 13%, Grade 3 in 10%, and Grade 4 in 17%. The median time to onset of the first thrombocytopenic event was 26.5 days. Thrombocytopenia resulted in dose reduction, dose interruption, or discontinuation in 9%, 2.8%, and 0.5% of patients, respectively. Grade 3 to 4 bleeding events occurred in 6% of patients, including Grade 4 in 1 patient. Fatal adverse reactions included cerebral hemorrhage in 2 patients. Perform complete blood cell counts at baseline and during treatment as clinically indicated. Consider withholding and/or reducing the dose based on severity.

     

    Infusion-Related Reactions: Infusion-related reactions occurred in 18% of 218 patients in the pooled safety population, including Grade 3 in 1.8%. Monitor patients for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion and provide supportive treatment. Once symptoms resolve, resume at a lower infusion rate. Administer premedication for all subsequent infusions. Discontinue BLENREP for life-threatening infusion-related reactions and provide appropriate emergency care.

     

    Embryo-Fetal Toxicity: Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose. Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.

     

    ADVERSE REACTIONS

    The pooled safety population described in Warnings and Precautions reflects exposure to BLENREP at a dosage of 2.5 mg/kg or 3.4 mg/kg (1.4 times the recommended dose) administered intravenously once every 3 weeks in 218 patients in DREAMM-2. Of these patients, 194 received a liquid formulation (not the approved dosage form) rather than the lyophilized powder.

     

    Patients received BLENREP at the recommended dosage of 2.5 mg/kg administered intravenously once every 3 weeks (n = 95). Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received BLENREP; keratopathy (2.1%) was the most frequent adverse reaction resulting in permanent discontinuation. Dosage interruptions due to an adverse reaction occurred in 54% of patients who received BLENREP. Adverse reactions which required a dosage interruption in >3% of patients included keratopathy (47%), blurred vision (5%), dry eye (3.2%), and pneumonia (3.2%). Dose reductions due to an adverse reaction occurred in 29% of patients. Adverse reactions which required a dose reduction in >3% of patients included keratopathy (23%) and thrombocytopenia (5%).

     

    The most common adverse reactions (≥20%) were keratopathy (71%), decreased visual acuity (53%), nausea (24%), blurred vision (22%), pyrexia (22%), infusion-related reactions (21%), and fatigue (20%). The most common Grade 3 or 4 (≥5%) laboratory abnormalities were lymphocytes decreased (22%), platelets decreased (21%), hemoglobin decreased (18%), neutrophils decreased (9%), creatinine increased (5%), and gamma-glutamyl transferase increased (5%).

     

    Serious adverse reactions occurred in 40% of patients who received BLENREP. Serious adverse reactions in >3% of patients included pneumonia (7%), pyrexia (6%), renal impairment (4.2%), sepsis (4.2%), hypercalcemia (4.2%), and infusion-related reactions (3.2%). Fatal adverse reactions occurred in 3.2% of patients, including sepsis (1%), cardiac arrest (1%), and lung infection (1%).

     

    USE IN SPECIFIC POPULATIONS

    Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with BLENREP and for 3 months after the last dose.

     

    Females and Males of Reproductive Potential: Based on findings in animal studies, BLENREP may impair fertility in females and males.

     

    Geriatric Use: Of the 218 patients who received BLENREP in DREAMM-2, 43% were aged 65 to less than 75 years and 17% were aged 75 years and older. Keratopathy occurred in 80% of patients aged less than 65 years and 73% of patients aged 65 years and older. Among the 95 patients who received BLENREP at the 2.5-mg/kg dose, keratopathy occurred in 67% of patients aged less than 65 years and 73% of patients aged 65 years and older.

     

    Renal or Hepatic Impairment: The recommended dosage has not been established in patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2) or end-stage renal disease (ESRD) with eGFR <15 mL/min/1.73 m2 not on dialysis or requiring dialysis. The recommended dosage has not been established in patients with moderate or severe hepatic impairment (total bilirubin >1.5 × ULN and any AST).

     

    Please see full Prescribing Information, including BOXED WARNING.

     

    VO: If you have questions, please call us at 1-855-209-9188.

    TEXT ON SCREEN: Enroll your patients at

    BLENREPHCP.com

    Call us at 1-855-209-9188

     

    TEXT ON SCREEN: BLENREP

    belantamab mafodotin-blmf

    for injection 100 mg

     

    Please see full Prescribing Information, including BOXED WARNING.

    Trademarks are owned by or licensed to the GSK group of companies.

    ©2021 GSK or licensor.

    BLMVID210002 August 2021

    Produced in USA.

RELATED VIDEOS

Eye Drop Program Enrollment Form

DOWNLOAD

Eye Drop Instruction Manual

DOWNLOAD